The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial.

[1]  H. Bøtker,et al.  Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart , 2017, Cardiovascular research.

[2]  N. Kalia,et al.  Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery , 2016, Basic Research in Cardiology.

[3]  B. Gersh,et al.  The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. , 2016, European heart journal.

[4]  H. Bøtker,et al.  Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations , 2016, European heart journal.

[5]  J. DiNicolantonio,et al.  Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  U. Frey,et al.  Myocardial protection by remote ischaemic pre‐conditioning is abolished in sulphonylurea‐treated diabetics undergoing coronary revascularisation , 2014, Acta anaesthesiologica Scandinavica.

[7]  F. Gaita,et al.  Remote ischaemic preconditioning in coronary artery bypass surgery: a meta-analysis , 2012, Heart.

[8]  M. Hellmich,et al.  Ischemic Preconditioning for Prevention of Contrast Medium–Induced Nephropathy: Randomized Pilot RenPro Trial (Renal Protection Trial) , 2012, Circulation.

[9]  M. Budoff,et al.  Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22 740 patients , 2012, Heart.

[10]  J. Spertus,et al.  Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. , 2012, Archives of Internal Medicine.

[11]  C. Terkelsen,et al.  Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial , 2010, The Lancet.

[12]  L. Sharples,et al.  Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: A Prospective, Randomized Control Trial , 2009, Circulation.

[13]  Jeremiah R. Brown,et al.  Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: Insights from the Dartmouth Dynamic Registry , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  M. Mihatsch,et al.  Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[16]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[17]  F. Veglia,et al.  N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .

[18]  R. Mehran,et al.  Contrast-induced nephropathy: definition, epidemiology, and patients at risk. , 2006, Kidney international. Supplement.

[19]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[20]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[21]  A. Levin,et al.  A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. , 2004, American heart journal.

[22]  S. Sdringola,et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[24]  E. Topol,et al.  Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy , 2002, Circulation.

[25]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.

[26]  Kirk N. Garratt,et al.  Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.

[27]  M. Brezis,et al.  Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. , 1999, Investigative radiology.

[28]  G. Taylor,et al.  Oxygen free radicals and contrast nephropathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[30]  P. Balakumar,et al.  Healing the diabetic heart: does myocardial preconditioning work? , 2012, Cellular signalling.

[31]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .